G1 Therapeutics, Inc. (GTHX)
| Market Cap | 193.24M |
| Revenue (ttm) | 24.16M |
| Net Income (ttm) | -171.10M |
| Shares Out | 42.71M |
| EPS (ttm) | -3.54 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 550,895 |
| Open | 4.44 |
| Previous Close | 4.63 |
| Day's Range | 4.40 - 4.74 |
| 52-Week Range | 4.25 - 24.12 |
| Beta | 1.92 |
| Analysts | Buy |
| Price Target | 40.29 (+790.4%) |
| Earnings Date | May 4, 2022 |
About GTHX
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for ...
Financial Performance
In 2021, GTHX's revenue was $31.48 million, a decrease of -30.49% compared to the previous year's $45.29 million. Losses were -$148.35 million, 49.5% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is 40.29, which is an increase of 790.39% from the latest price.
News
G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference
RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1's Chief Executive Officer, ...
G1 Therapeutics (GTHX) Reports Q1 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -16.16% and 19.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Provides First Quarter 2022 Financial Results and Operational Highlights
- Achieved $6.9 Million in Total Revenue in the First Quarter of 2022, Including $5.5 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 02, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisabl...
Earnings Preview: G1 Therapeutics (GTHX) Q1 Earnings Expected to Decline
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics to Release First Quarter 2022 Financial Results and Provide Business Update on May 4, 2022
RESEARCH TRIANGLE PARK, N.C., April 21, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate...
G1 Therapeutics to Participate in the 21st Annual Needham Virtual Healthcare Conference
RESEARCH TRIANGLE PARK, N.C., April 06, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey and Raj Malik, M.D., G1's Chi...
New Real-World Data Show Potential of Trilaciclib to Reduce the Substantial Burden of Myelosuppression in Patients wi...
Data being presented at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference Data being presented at the National Comprehensive Cancer Network (NCCN) 2022 Annual Conference
G1 Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference and the 34th Annual Roth 2022 Conference
RESEARCH TRIANGLE PARK, N.C., March 01, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcom...
G1 Therapeutics (GTHX) Reports Q4 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 8.74% and 6.31%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics Provides Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
- Achieved $5.8 Million in Total Revenue in the Fourth Quarter of 2021, Including $4.4 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -
G1 Therapeutics to Provide Fourth Quarter and Full Year 2021 Financial Results and Business Update on February 23, 2022
RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate ...
G1 Therapeutics to Participate in the 40th Annual J.P. Morgan and H.C.
RESEARCH TRIANGLE PARK, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcomi...
G1 Therapeutics Announces Expansion of COSELA™ (Trilaciclib) Sales Force
- G1 and Boehringer Ingelheim Mutually Agree to End Co-Promotion Agreement -
G1 Therapeutics Initiates Phase 2 Trial to Support the Antitumor Mechanism of Action (MOA) of Trilaciclib in the Tumo...
New Trial Designed to Further Investigate the Immune-Based MOA of Trilaciclib and Help Determine Future Target Tumor Types and Treatment Combinations New Trial Designed to Further Investigate the Immune...
G1 Therapeutics Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with the Antibody-Drug Conjug...
Trial Will Evaluate Anti-Tumor Efficacy and Myeloprotection Endpoints in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) Trial Will Evaluate Anti-Tumor Eff...
Immune Analysis from Phase 2 Triple Negative Breast Cancer Trial Demonstrates Trilaciclib Enhanced Patients' T Cell I...
- Exploratory Analysis Investigated Immune Mechanisms Underlying The Significant Improvement In Overall Survival Shown In The Phase 2 TNBC Trial, Results Of Which Were Presented At 2020 San Antonio Brea...
G1 Therapeutics to Participate in Two Upcoming Conferences
RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcomi...
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 2.91% and 12.85%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: G1 Therapeutics Q3 Earnings
G1 Therapeutics (NASDAQ:GTHX) reported its Q3 earnings results on Wednesday, November 3, 2021 at 08:00 AM. Here's what investors need to know about the announcement.
G1 Therapeutics Provides Third Quarter 2021 Financial Results and Operational Highlights
- Achieved $4.9 Million in Total Revenue, Including $3.6 Million in Net Revenue from Sales of COSELA™ (trilaciclib) -
Earnings Preview: G1 Therapeutics (GTHX) Q3 Earnings Expected to Decline
G1 Therapeutics (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 Therapeutics to Provide Third Quarter 2021 Financial Results and Business Update on November 3, 2021
RESEARCH TRIANGLE PARK, N.C., Oct. 20, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate ...
Retrospective Analysis of Pooled Results from Three Studies Shows COSELA™ (Trilaciclib) Reduced Use of Supportive Car...
Proactive use of trilaciclib prior to chemotherapy in certain patients significantly reduced the use of G-CSFs, ESAs, and RBC transfusions on or after week five of chemotherapy Proactive use of trilacic...
G1 Therapeutics Announces Permanent J-Code from Centers for Medicare and Medicaid Services
Effective Today, New J-code to Streamline Reimbursement Effective Today, New J-code to Streamline Reimbursement